Product
Recombinant COVID-19 variant Vaccine
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster Following Primary Vaccination of Either Inactivated or mRNA or Viral Vector COVID-19 VaccinesStatus: Active (not recruiting), Estimated PCD: 2024-11-30